What are the expected plasma levels of levofloxacin (a fluoroquinolone antibiotic) in a patient with end-stage renal disease (ESRD) on dialysis after taking a 500mg dose on day 1?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 18, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Plasma Levels of Levofloxacin in Dialysis Patients After 500mg on Day 1

After a single 500mg dose of levofloxacin in hemodialysis patients, expect a peak plasma concentration (Cmax) of approximately 5.2 μg/mL occurring 1-2 hours post-dose, with trough levels around 2.7-2.9 μg/mL before the next dialysis session. 1

Peak and Trough Concentrations

  • Peak levels (Cmax): Following a 500mg intravenous dose administered after hemodialysis, median peak concentrations reach 5.2 μg/mL (range 4.1-11.3 μg/mL) within 1-2 hours 1

  • Trough levels: Before the next dialysis session (approximately 48 hours later), trough concentrations average 2.7 μg/mL (range 1.4-5.0 μg/mL) 1

  • Oral versus IV equivalence: Oral and intravenous levofloxacin achieve essentially identical plasma exposures at the same dose, with oral bioavailability approaching 100% 2, 1

Pharmacokinetic Parameters in ESRD

The pharmacokinetics of levofloxacin are dramatically altered in end-stage renal disease patients on hemodialysis compared to those with normal renal function:

  • Elimination half-life: Prolonged to 34.4 hours (range 28.4-39.3 hours) in hemodialysis patients versus 6-8 hours in normal renal function 1, 2

  • Systemic clearance: Reduced to 37.0 mL/min (range 12.8-42.7 mL/min) in ESRD patients 1

  • Volume of distribution: Approximately 103.3 L (range 39.8-139.3 L) or 1.1 L/kg, similar to patients with normal renal function 1, 2

Impact of Hemodialysis on Drug Removal

  • Dialytic clearance: Hemodialysis removes levofloxacin with a median clearance of 84.4 mL/min (range 61.8-107.6 mL/min) using a cellulose acetate high-performance dialyzer 1

  • Reduction ratio: Approximately 24.4% (range 18.1-41.2%) of levofloxacin is removed during a single hemodialysis session 1

  • Critical timing: Because approximately 80% of levofloxacin undergoes renal clearance, the drug is significantly removed by dialysis, making post-dialysis administration essential 3, 2

Therapeutic Adequacy

The 500mg dose on day 1 provides therapeutically adequate concentrations for most respiratory pathogens:

  • Cmax/MIC90 ratios ≥10: Achieved for Haemophilus influenzae, Moraxella catarrhalis, Enterobacter cloacae, and Klebsiella pneumoniae 1

  • Cmax/MIC90 ratio ~5: Achieved for Streptococcus pneumoniae 1

  • Inadequate coverage: Pseudomonas aeruginosa (Cmax/MIC90 <1) requires higher doses 1

Recommended Dosing Strategy

For hemodialysis patients, administer 500mg initially on day 1, followed by 250mg every 48 hours (or 750-1000mg three times weekly after each dialysis session for tuberculosis). 3, 4, 1

  • The loading dose of 500mg ensures adequate initial concentrations 1

  • Maintenance doses of 250mg every 48 hours prevent drug accumulation while maintaining therapeutic levels for organisms with MIC ≤1 μg/mL 1

  • For tuberculosis treatment specifically, higher doses of 750-1000mg three times weekly are recommended by the American Thoracic Society 3, 4, 5

Critical Pitfalls to Avoid

  • Never administer before dialysis: This results in premature drug removal and therapeutic failure 3, 4, 5

  • Avoid daily dosing: Daily administration leads to drug accumulation and increased neurotoxicity risk in dialysis patients 6, 5

  • Drug interactions: Do not administer within 2 hours of antacids or medications containing divalent cations (aluminum, magnesium, iron, calcium), as these dramatically reduce levofloxacin absorption 3, 6, 2

Monitoring Considerations

  • Therapeutic drug monitoring: Consider measuring serum concentrations at 2 and 6 hours post-dose to optimize dosing in patients with borderline renal function or multiple comorbidities 4, 6, 5

  • Neurotoxicity surveillance: Monitor for central nervous system toxicity, particularly in elderly patients, as this is a well-recognized complication in renal impairment 5

References

Research

Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2003

Research

The clinical pharmacokinetics of levofloxacin.

Clinical pharmacokinetics, 1997

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Dosificación y Administración de Levofloxacino en Pacientes con Enfermedad Renal Crónica

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Levofloxacin Dosing for Female Patients on Hemodialysis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Levofloxacin Dosing for CRRT

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What is the recommended dose and administration schedule of levofloxacin (Levofloxacino) in relation to hemodialysis in patients with chronic kidney disease (CKD)?
What if a dose of levofloxacin (a fluoroquinolone antibiotic) falls on a non-dialysis day for a patient with end-stage renal disease (Impaired renal function) on hemodialysis, can the next dose be given the following day after dialysis?
What is the recommended dose of Levofloxacin for a patient undergoing Hemodialysis (HD)?
What is the recommended dose of levofloxacin (Levaquin) for patients with End-Stage Renal Disease (ESRD)?
What is the recommended dose of levof Tours (levofloxacin) for a patient with stage 4 Chronic Kidney Disease (CKD) and pseudomonas pneumonia?
What size Vicryl (polyglactin 910) suture is preferred for a cesarean delivery?
What is the new classification of diabetes, particularly for patients with type 2 diabetes at risk of diabetic foot?
What are the potential causes of bilateral pitting pedal edema that worsens in the evening and swelling in the face and periorbital region in a patient with a 10-day history of pedal edema and a 3-day history of facial swelling?
What is the approach to managing precipitous labour in a low-risk multiparous woman with no significant medical history in the Emergency Department (ED)?
What is the significance of an elevated D-dimer (D-dimer) level in a patient with decompensated heart failure?
What is HELLP (Hemolysis, Elevated Liver enzymes, and Low Platelet count) syndrome in a pregnant woman?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.